GSK plc vs Prospect Capital Corporation — how do they compare? GSK plc trades at $50.35 (market cap $102.60B), while Prospect Capital Corporation trades at $2.29 (market cap $1.14B). The key difference: GSK plc is far larger — about 90× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (21.93%). Which is the better fit depends on your goals.
| GSK | PSEC | |
|---|---|---|
Market Cap | $102.60B | $1.14B |
Sector | Health | Financials |
52-Week High | $61.18 | $3.05 |
52-Week Low | $38.22 | $2.11 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | 21.93% |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
Prospect Capital Corporation (PSEC) trades at $2.285, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows mixed fundamentals with a low P/B ratio of 0.39 but negative revenue and net income margins. Recent earnings have consistently beaten expectations, and the company maintains regular dividend payments of $0.04 per share. Analyst sentiment is divided with 25% buy ratings, 55% hold, and 20% sell recommendations.
PSEC presents a high-risk, high-yield opportunity trading at a significant discount to book value. The investment case hinges on the company's ability to stabilize revenue and return to profitability while maintaining its dividend distribution. Key risks include persistent negative revenue trends, high leverage costs, and market skepticism about portfolio quality despite recent successful exits like the Valley Electric sale generating 4.8x returns.
Trailing returns across standard periods
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →